{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT05757141",
            "orgStudyIdInfo": {
                "id": "M23-523"
            },
            "organization": {
                "fullName": "Calico Life Sciences LLC",
                "class": "INDUSTRY"
            },
            "briefTitle": "An Open-Label Exploratory Study of ABBV-CLS-7262 Subjects With Vanishing White Matter Disease",
            "officialTitle": "A Phase 1b/2 Open-label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Exploratory Efficacy Following ABBV-CLS-7262 Administration in Adult and Pediatric Subjects With Vanishing White Matter Disease",
            "therapeuticArea": [
                "Other"
            ],
            "study": "an-open-label-exploratory-study-of-abbv-cls-subjects-with-vanishing-white-matter-disease"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-05",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2023-03-13",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2026-10",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2026-10",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2023-02-23",
            "studyFirstSubmitQcDate": "2023-03-03",
            "studyFirstPostDateStruct": {
                "date": "2023-03-07",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-05-24",
            "lastUpdatePostDateStruct": {
                "date": "2024-05-28",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "Calico Life Sciences LLC",
                "class": "INDUSTRY"
            },
            "collaborators": [
                {
                    "name": "AbbVie",
                    "class": "INDUSTRY"
                }
            ]
        },
        "oversightModule": {
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
            "briefSummary": "ABBV-CLS-7262 is an investigational drug being researched for the treatment of Vanishing White Matter disease in adult and pediatric subjects. This is a 96-week, open-label, multiple cohort study enrolling adults and pediatric subjects with Vanishing White Matter disease who are 6 years or older.\n\nSubjects will attend regular visits during the course of the study and complete medical assessments, blood tests, checking for side effects, and completing questionnaires."
        },
        "conditionsModule": {
            "conditions": [
                "Vanishing White Matter Disease"
            ],
            "keywords": [
                "Neurodegenerative Diseases",
                "Nervous System Diseases",
                "Central Nervous System Brain Diseases",
                "Hereditary Central Nervous System",
                "Leukoencephalopathy with Vanishing White Matter"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE1",
                "PHASE2"
            ],
            "designInfo": {
                "allocation": "RANDOMIZED",
                "interventionModel": "SINGLE_GROUP",
                "primaryPurpose": "TREATMENT",
                "maskingInfo": {
                    "masking": "NONE"
                }
            },
            "enrollmentInfo": {
                "count": 14,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "ABBV-CLS-7262 - Cohort 1",
                    "type": "EXPERIMENTAL",
                    "description": "Cohort 1: VWM adults \u226518 years",
                    "interventionNames": [
                        "Drug: ABBV-CLS-7262"
                    ]
                },
                {
                    "label": "ABBV-CLS-7262 - Cohort 2",
                    "type": "EXPERIMENTAL",
                    "description": "Cohort 2: VWM children \u226512 y and \\<18 years",
                    "interventionNames": [
                        "Drug: ABBV-CLS-7262"
                    ]
                },
                {
                    "label": "ABBV-CLS-7262 - Cohort 3",
                    "type": "EXPERIMENTAL",
                    "description": "Cohort 3: VWM children \u22656 y and \\<12 years",
                    "interventionNames": [
                        "Drug: ABBV-CLS-7262"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DRUG",
                    "name": "ABBV-CLS-7262",
                    "description": "Active Drug: ABBV-CLS-7262 - Oral",
                    "armGroupLabels": [
                        "ABBV-CLS-7262 - Cohort 1",
                        "ABBV-CLS-7262 - Cohort 2",
                        "ABBV-CLS-7262 - Cohort 3"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]",
                    "description": "Number of patients with treatment-related adverse events as assessed by CTCAE v4.03",
                    "timeFrame": "Baseline up to Approximately Day 49"
                },
                {
                    "measure": "Plasma Concentration",
                    "description": "Maximum Plasma Concentration \\[Cmax\\]",
                    "timeFrame": "Baseline up to approximately Week 96"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]",
                    "description": "Number of patients with treatment-related adverse events as assessed by CTCAE v4.03",
                    "timeFrame": "Baseline up to Approximately Week 100"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\n1. Males and females \u22656 years of age at the time of Screening.\n2. Have VWM disease defined as:\n\n   1. A clinical diagnosis by a physician experienced in the assessment of VWM disease; and\n   2. A molecular diagnosis of VWM disease confirmed through mutation(s) in eIF2B, and\n   3. A magnetic resonance imaging (MRI) presentation consistent with VWM disease.\n3. Have a designated caregiver who is able to complete the respective caregiver-centered assessments.\n4. Signed and dated informed consent provided by the subject, or from a legally authorized representative (LAR) if subject is incapable to consent themselves.\n5. Subjects must meet functional criteria related to ambulation and cognition; specific details can be provided by the Study physician.\n6. All male subjects who are sexually active and not surgically sterilized must agree to use an acceptable contraceptive method. Additionally, male subjects must agree to not donate sperm during the study until 30 days after the final dose of study drug.\n7. All female subjects who are sexually active and of childbearing potential must agree to use a highly effective contraceptive method. Additionally, female subjects must agree to not donate eggs during the study and for 30 days after the final dose of study drug.\n\nExclusion Criteria:\n\n1. Changes in medication use for the management of VWM disease symptoms within the 4 weeks preceding Screening.\n2. Seizure disorder not considered adequately controlled by the investigator within the 6 months preceding Screening.\n3. Subject who, in the opinion of the investigator, is incapable of completing study-required visits and procedures to assess primary and secondary endpoints.\n4. Pregnant or breastfeeding.\n5. Treatment with any other investigational treatment within 30 days or 5 half-lives (whichever is longer) prior to Baseline.",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "6 Years",
            "stdAges": [
                "CHILD",
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Calico Call Center-English",
                    "role": "CONTACT",
                    "phone": "1-833-250-9660",
                    "email": "vwminfo@mylocalstudy.com"
                }
            ],
            "locations": [
                {
                    "facility": "Massachusetts General Hospital",
                    "status": "NOT_YET_RECRUITING",
                    "city": "Boston",
                    "state": "Massachusetts",
                    "zip": "02114",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Julie Tassinari",
                            "role": "CONTACT",
                            "phone": "617-530-0615",
                            "email": "jtassinari1@bwh.harvard.edu"
                        }
                    ],
                    "geoPoint": {
                        "lat": 42.35843,
                        "lon": -71.05977
                    }
                },
                {
                    "facility": "University of Utah Hospital",
                    "status": "RECRUITING",
                    "city": "Salt Lake City",
                    "state": "Utah",
                    "zip": "84112",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Joshua Bonkowsky",
                            "role": "CONTACT",
                            "phone": "801-213-3599",
                            "email": "Joshua.bonkowsky@hsc.utah.edu"
                        }
                    ],
                    "geoPoint": {
                        "lat": 40.76078,
                        "lon": -111.89105
                    }
                },
                {
                    "facility": "Amsterdam UMC - Department of Neurology",
                    "status": "RECRUITING",
                    "city": "Amsterdam",
                    "country": "Netherlands",
                    "contacts": [
                        {
                            "name": "Prof. Dr. M.S. van der Knaap",
                            "role": "CONTACT",
                            "email": "ms.vanderknaap@amsterdamumc.nl"
                        }
                    ],
                    "geoPoint": {
                        "lat": 52.37403,
                        "lon": 4.88969
                    }
                }
            ]
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000056784",
                    "term": "Leukoencephalopathies"
                }
            ],
            "ancestors": [
                {
                    "id": "D000001927",
                    "term": "Brain Diseases"
                },
                {
                    "id": "D000002493",
                    "term": "Central Nervous System Diseases"
                },
                {
                    "id": "D000009422",
                    "term": "Nervous System Diseases"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M21558",
                    "name": "Neurodegenerative Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M5204",
                    "name": "Brain Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M28591",
                    "name": "Leukoencephalopathies",
                    "asFound": "Vanishing White Matter Disease",
                    "relevance": "HIGH"
                },
                {
                    "id": "M5742",
                    "name": "Central Nervous System Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "T3402",
                    "name": "Leukoencephalopathy With Vanishing White Matter",
                    "asFound": "Vanishing White Matter Disease",
                    "relevance": "HIGH"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC10",
                    "name": "Nervous System Diseases"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                },
                {
                    "abbrev": "Rare",
                    "name": "Rare Diseases"
                }
            ]
        }
    },
    "hasResults": false
}